STEK (Stemtech) Moat Score: 1/10 (As of Jun. 30, 2026)


What is Stemtech Moat Score?

Stemtech STEK Moat Score is 1 as of Jun. 30, 2026. The stock has 6 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Stemtech ranks better than 76.21% on this metric.

Stemtech has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Stemtech has No Moat: Stemtech Corp lacks market leadership, brand strength, and significant intellectual property in the health and wellness sector. The company faces intense competition and has no durable cost advantages or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Stemtech might have No Moat - Very weak/transient advantages.

Stemtech  (OTCPK:STEK) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Stemtech Moat Score Related Terms

STEK vs PTPI, KOAN, GCAN: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Stemtech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stemtech Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Stemtech's Moat Score distribution charts can be found below:

* The bar in red indicates where Stemtech's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Stemtech (STEK) has a Moat Score of 1 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Stemtech ranks #245 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 23.8%.
Is Stemtech's Moat Score too high?
Stemtech's current Moat Score is 1. Based on the distribution chart, Stemtech ranks #245 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Stemtech's Moat Score compare to PTPI and KOAN?
According to the Drug Manufacturers industry distribution chart, Stemtech ranks #245 out of 1030 companies for Moat Score. This places Stemtech in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Stemtech's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stemtech stock overvalued right now?
Based on GuruFocus' analysis, Stemtech (STEK) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Moat Score is 1. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Stemtech (STEK), the current Moat Score is 1 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stemtech Business Description

Address 4851 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate into tissues, where the stem cells perform their daily function of renewal for optimal health. It markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Geographically, it derives a majority of its revenue from Latin America.